10/30/2020  11:11:09 AM Chg. +0.0200 Volume Bid5:36:12 PM Ask5:36:12 PM Market Capitalization Dividend Y. P/E Ratio
1.7600EUR +1.15% 1,700
Turnover: 2,992
-Bid Size: - -Ask Size: - 92.07 mill.EUR 0.00% -

Business description

The Company focuses on the development of novel products in molecular biology, with one focus on polymerases with multitudinous applications in the field of DNA amplification and sequencing and another one on innovative technologies around protein-protein interactions.
 

Management board & Supervisory board

CEO
Dr. Heikki Lanckriet
Management board
David Roth
Supervisory board
Joseph M. Fernández, Dr. Trevor Jarman, Hansjörg Plaggemars, Peter Llewellyn-Davies, Pilar de la Huerta, Tim McCarthy
 

Company data

Name: 4basebio AG
Address: Waldhofer Str. 102,D-69123 Heidelberg
Phone: +49-6221-3540-120
Fax: +49-6221-3540-127
E-mail: info@4basebio.com
Internet: www.4basebio.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 65.87%
IPO date: 8/11/2000

Investor relations

Name: Dr. Robert Mayer
IR phone: +49-6221-3540-125
IR Fax: +49-6221-3540-127
IR e-mail: www.investors.4basebio.com

Company calendar

CW 45 | 11/3/2020 Extraordinary General Meeting
CW 46 | 11/12/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
65.87%
Deutsche Balaton Aktiengesellschaft, SPARTA AG
 
21.89%
Fernandez Family Trust
 
5.54%
Franciscus De Busschere
 
3.50%
Dr. Heikki Lanckriet
 
3.20%